Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America
- PMID: 40392909
- PMCID: PMC12091891
- DOI: 10.1371/journal.pmed.1004590
Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America
Abstract
Background: Alcohol is a known carcinogen, yet the evidence for an association with pancreatic cancer risk is considered as limited or inconclusive by international expert panels. We examined the association between alcohol intake and pancreatic cancer risk in a large consortium of prospective studies.
Methods and findings: Population-based individual-level data was pooled from 30 cohorts across four continents, including Asia, Australia, Europe, and North America. A total of 2,494,432 participants without cancer at baseline (62% women, 84% European ancestries, 70% alcohol drinkers [alcohol intake ≥ 0.1 g/day], 47% never smokers) were recruited between 1980 and 2013 at the median age of 57 years and 10,067 incident pancreatic cancer cases were recorded. In age- and sex-stratified Cox proportional hazards models adjusted for smoking history, diabetes status, body mass index, height, education, race and ethnicity, and physical activity, pancreatic cancer hazard ratios (HR) and 95% confidence intervals (CI) were estimated for categories of alcohol intake and in continuous for a 10 g/day increase. Potential heterogeneity by sex, smoking status, geographic regions, and type of alcoholic beverage was investigated. Alcohol intake was positively associated with pancreatic cancer risk, with HR30-to-<60 g/day and HR≥60 g/day equal to 1.12 (95% CI [1.03,1.21]) and 1.32 (95% CI [1.18,1.47]), respectively, compared to intake of 0.1 to <5 g/day. A 10 g/day increment of alcohol intake was associated with a 3% increased pancreatic cancer risk overall (HR: 1.03; 95% CI [1.02,1.04]; pvalue < 0.001) and among never smokers (HR: 1.03; 95% CI [1.01,1.06]; pvalue = 0.006), with no evidence of heterogeneity by sex (pheterogeneity = 0.274) or smoking status (pheterogeneity = 0.624). Associations were consistent in Europe-Australia (HR10 g/day = 1.03, 95% CI [1.00,1.05]; pvalue = 0.042) and North America (HR10 g/day = 1.03, 95% CI [1.02,1.05]; pvalue < 0.001), while no association was observed in cohorts from Asia (HR10 g/day = 1.00, 95% CI [0.96,1.03]; pvalue = 0.800; pheterogeneity = 0.003). Positive associations with pancreatic cancer risk were found for alcohol intake from beer (HR10 g/day = 1.02, 95% CI [1.00,1.04]; pvalue = 0.015) and spirits/liquor (HR10 g/day = 1.04, 95% CI [1.03,1.06]; pvalue < 0.001), but not wine (HR10 g/day = 1.00, 95% CI [0.98,1.03]; pvalue = 0.827). The differential associations across geographic regions and types of alcoholic beverages might reflect differences in drinking habits and deserve more investigations.
Conclusions: Findings from this large-scale pooled analysis support a modest positive association between alcohol intake and pancreatic cancer risk, irrespective of sex and smoking status. Associations were particularly evident for baseline alcohol intake of at least 15 g/day in women and 30 g/day in men.
Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Conflict of interest statement
I have read the journal's policy and the authors of this manuscript have the following competing interests: MS is employed at IQVIA, a contract research company, and has no financial stake in the results of the current study. WZ and SCM are Academic Editors on PLOS Medicine's editorial board.
Figures
Comment in
-
Power in numbers: Harnessing global data to unravel the alcohol-pancreatic cancer link.PLoS Med. 2025 May 22;22(5):e1004615. doi: 10.1371/journal.pmed.1004615. eCollection 2025 May. PLoS Med. 2025. PMID: 40403017 Free PMC article.
References
-
- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. - PubMed
-
- Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM-L, Myklebust TÅ, et al.. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–505. doi: 10.1016/S1470-2045(19)30456-5 . - DOI - PMC - PubMed
-
- Cabasag CJ, Ferlay J, Laversanne M, Vignat J, Weber A, Soerjomataram I. Pancreatic cancer: an increasing global public health concern. Gut. 2021. - PubMed
MeSH terms
Grants and funding
- 75N92021D00002/HL/NHLBI NIH HHS/United States
- U01 CA176726/CA/NCI NIH HHS/United States
- UM1 CA173640/CA/NCI NIH HHS/United States
- 75N92021D00001/HL/NHLBI NIH HHS/United States
- R01 AA024770/AA/NIAAA NIH HHS/United States
- R01 CA039742/CA/NCI NIH HHS/United States
- P30 CA033572/CA/NCI NIH HHS/United States
- U01 CA199277/CA/NCI NIH HHS/United States
- UM1 CA164917/CA/NCI NIH HHS/United States
- U01 CA210171/CA/NCI NIH HHS/United States
- U01 HL145386/HL/NHLBI NIH HHS/United States
- 75N92021D00005/WH/WHI NIH HHS/United States
- U01 CA063673/CA/NCI NIH HHS/United States
- U01 CA167462/CA/NCI NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- R01 CA144034/CA/NCI NIH HHS/United States
- U01 CA167552/CA/NCI NIH HHS/United States
- U01 CA086308/CA/NCI NIH HHS/United States
- 75N92021D00003/WH/WHI NIH HHS/United States
- UM1 CA186107/CA/NCI NIH HHS/United States
- P30 CA023100/CA/NCI NIH HHS/United States
- R01 CA077398/CA/NCI NIH HHS/United States
- UM1 CA167462/CA/NCI NIH HHS/United States
- 001/WHO_/World Health Organization/International
- U01 CA164973/CA/NCI NIH HHS/United States
- 75N92021D00004/WH/WHI NIH HHS/United States
- U01 AG018033/AG/NIA NIH HHS/United States
- UM1 CA182876/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
